Table 1.
Patients’ characteristics based on antiretroviral therapy regimens administered in the last four years.
| Therapy | ||||
|---|---|---|---|---|
|
Group 1
Backbone plus NNRTI (EFV or ETV or RPV) |
Group 2
Backbone plus NNRTI (NVP) |
Group 3
Backbone plus PI/r (DRV/r) |
Group 4
INI (RAL) plus PI/r (DRV/r) |
|
| N° of patients | 39 | 42 | 41 | 39 |
| Age | 41 (IQR, 38-48) | 49 (IQR, 42-55) | 45 (IQR, 42-51) | 48 (IQR, 42-55) |
| Male, no (%) | 87 | 76 | 92 | 79 |
| Risk group, no (%): Homo/bisexual | 62 | 60 | 56 | 52 |
| Risk group, no (%): Heterosexual | 34 | 38 | 37 | 43 |
| Risk group, no (%): Drug user | 4 | 2 | 7 | 5 |
| Duration of current cART (years) | 4.4 (IQR, 3.9-4.8) | 4.5 (IQR, 4.1-5.2) | 4.2 (IQR, 3.6-5.5) | 4.3 (IQR, 3.6-5.1) |
| Zenith HIV RNA (log copies/ml) | 4.96 (IQR, 4.58-5.28) | 4.80 (IQR, 4.30-5.38) | 4.45 (IQR, 4.00-4.95) | 4.00 (IQR, 4.00-5.08) |
| Current CD4 cell count (cells/mm3) | 706 (IQR, 589-925) | 660 (IQR, 521-849) | 776 (IQR, 577-943) | 789 (IQR, 589-1045) |
| Nadir CD4 cell count (cells/mm3) | 319 (IQR, 257-400) | 296 (IQR, 160-240) | 290 (IQR, 176-396) | 284 (IQR, 71-390) |
Data are median (IQR, interquartile range) and values are expressed as n (%); cART, combination antiretroviral therapy; backbone: abacavir/lamivudine (ABC/3TC) or emtricitabine/tenofovir diproxil (FTC/TDF); NNRTI: non-nucleoside reverse transcriptase inhibitors; EFV: Efavirenz; ETV: Etravirine; RPV: rilpivirine; NVP: Nevirapine; DRV/r: darunavir/ritonavir; INI: integrase inhibitor; RAL: Raltegravir.